Raloxifene analog LY 117018 effects on central and peripheral β-endorphin

Gynecological Endocrinology

Volumn 13, Issue 4, 1999, Pages 249-258

  Genazzani, A R ^a   Bernardi, F ^a   Stomati, M ^a   Rubino, S ^a   Giardina, L ^a   Luisi, S ^a   Monteleone, P ^a   Genazzani, A D ^b   Luisi, M ^c   Petraglia, F ^d  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c CNR   (Italy)

^d UNIVERSITY OF UDINE   (Italy)

Author keywords

LY 117018; Raloxifene; SERMs; endorphin

Indexed keywords

6 HYDROXY 2 (4 HYDROXYPHENYL) 3 [4 [2 (1 PYRROLIDINYL)ETHOXY]BENZOYL]BENZO[B]THIOPHENE; ANTIESTROGEN; BETA ENDORPHIN; ESTRADIOL; ESTROGEN RECEPTOR;

ADENOHYPOPHYSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST; CHEMICAL STRUCTURE; CONTROLLED STUDY; FEMALE; HIPPOCAMPUS; HYPOPHYSIS INTERMEDIATE LOBE; HYPOTHALAMUS; NEUROENDOCRINOLOGY; NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RAT; UTERUS;

EID: 0032887292     PISSN: 09513590     EISSN: None     Source Type: Journal    
DOI: 10.3109/09513599909167563     Document Type: Article

References (36)

1. MacGregor JI, Tonetti DA, Jordan VC. The complexity of selective estrogen receptor modulators: the design of a postmenopausal prevention maintenance therapy. In Lindsay R, Dempster DW, Jordan VC, eds. Estrogens and Antiestrogens. Philadelphia: Lippincott-Raven Publishers, 1997:261-77
2. Paech K, Webb P, Kuiper GJM, et al. Differential ligand activation of estrogen receptor ERα and ERβ at AP1 sites. Science 1997;277:1508-10
3. Barkhem T, Carlsson B, Nilsson Y, et al. Differential response of ERα and ERβ to partial estrogen agonists/antagonists. Mol Pharmacol 1998;54:105-12
4. Laflamme N, Nappi RE, Drolet G, et al. Expression and neuropeptidergic characterization of estrogen receptors (ERα and ERβ)throughout the rat brain: anatomical evidence of distinct roles of each subtype. J Neurobiol 1998;36:357-78
5. Shughruc PJ, Lane MV, Merchenthaler I, Regulation of progesterone receptor messenger ribonucleic acid in the rat medial preoptic nucleus by estrogenic and anti-estrogenic compounds: an in situ hybridization study. Endocrinology 1997;138:5476-84
6. Shughrue PJ, Komm B, Merchenthaler I. The distribution of estrogen receptor-beta mRNA in the rat hypothalamus. Steroids 1996;61:678-81
7. Hamm JT, Tormey DC, Kohler PC, et al. Phase I study of toremifene in patients wth advanced cancer. J Clin Oncol 1991;9:2036-41
8. Szamel I, Hindy I, Vincze B, et al. Influence of toremifene on the endocrine regulation in breast cancer patients. Eur J Cancer 1994;30:154-8
9. Ortmann O, Emons G, Knuppen R, et al. Inhibitory actions of keoxifene on luteinizing hormone secretion in pituitary gonadotrophs. Endocrinology 1988;123:962-8
10. Clemens JA, Bennett DR, Black LJ, et al. Effects of a new anti-estrogen, Keoxifene LY156758, on growth of carcinogen induced mammary tumors and on LH and prolactin levels. Life Sci 1983:2869-75
11. Gray JM, Ziemian L. Anti-estrogen binding sites in brain and pituitary of ovariectomized rats. Brain Res 1992;578:55-60
12. Petersen SL, Barraclough CA. Suppression of spontaneous LH surges in estrogen treated ovariectomized rats by microimplants of antiestrogens into the preoptic brain. Brain Res 1989;484:279-89
13. Meisel RL, Dohanich GP, McEwen BS, et al. Antagonism of sexual behaviour in Female rats by ventromedial hypothalamic implants of anti-estrogen. Neuroendocrinology 1987;45:201-7
14. Early Breast Cancer Trials Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. Lancet 1992;339:71-85
15. Merchenthaler I, Funkhouser JM, Carver JM, et al. The effect of estrogens and anti-estrogens in a rat model for hot flush. Maturitas 1998;30:307-16
16. Nilsen J, Mor G, Naftolin F. Raloxifene induces neurite outgrowth in estrogen receptor positive PC12 cells. Menopause 1998;5:211-16
17. Petraglia F, Panerai AE, Rivier C, et al. Opioid control of gonadotropin secretion. In Genazzani AR, Montemagno U, Nappi C, et al, eds. The Brain and Female Reproductive Function Carnforth, UK: Parthenon Publishing, 1987:65-71
18. Piva F, Limonta P, Maggi R, et al. Dual effects of the opioids in the control of gonadotropin secretion. In Delitala G, Motta M, Serio M, eds. Opiod Modulation of Endocrine Function. New York: Raven Press, 1984:155-9
19. Locatelli V, Petraglia F. Gonadal steroid modulation of brain and pituitary β-endorphin. In Camanni F and Muller EE, eds. Pituitary Hyperfunction: Physiopathology and Clinical Aspects. New York: Raven Press, 1984:35-40
20. Jirikowski GF, Merchenthaler I, Rieger GE, et al. Estradiol target sites immunoreactive for β-endorphin in the arcuate nucleus of rat and mouse hypothalamus, Neurosci Lett 1986;65:121-5
21. Genazzani AR, Petraglia F, Mercuri N. et al. Effects of steroid hormones and antihormones on hypothalamic β-endorphin concentrations in intact and castrated female rats. J Endocrinol Invest 1990;13:91-6
22. Petraglia F, Penalva A, Locatelli V, et al. Effect of gonadectomy and gonadal steroid replacement on pituitary and plasma β-endorphin levels in rats. Endocrinology 1982;111:1224-9
23. Bradford M. A rapid and sensitive method for quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Annal Biochem 1976;72:248-59
24. Speroff L, Glass RH, Kase NH. Clinical Gynecological Endocrinology and Infertility, 5th edn. Baltimore, Maryland: Williams & Wilkins
25. Petraglia F, Locatelli V, Facchinetti F, et al. Oestrus cycle-related LH responsiveness to naloxone: effect of high oestrogen levels on the activity of opioid receptors J Endorcrinol 1986;108:89-94
26. Barden N, Merand Y, Rouleau D, et al. Changes in the β-endorphin content of discrete hypothalamic nuclei during the estrous cycle of the rat. Brain Res 1981;204:441-5
27. Knuth UA, Sikand GS, Casanueva FF, et al. Changes in β-endorphin content in discrete areas of the hypothalamus throughout proestrus and diestrus of the rat. Life Sci 1983;33:1443-50
28. Genazzani AR, Petraglia F, Facchinetti F, et al. Increase of pro-opiomelanocortin related peptides during subjective menopausal flushes. Am J Obstet Gynecol 1984;149:775-9
29. Linghtman SL, Jacobs HS, Maguire AK. Climacteric flushing: clinical and endocrine response to infusion of naloxone. Br J Obstet Gynecol 1981;88:919-24
30. Stomati M, Bersi C, Rubino S, et al. Neuroendocrine effects of different oestradiol-progestin regimens in postmenopausal women. Maturitas 1997;28:127-35
31. Genazzani AR, Petraglia F, Facchinetti F, et al. Effect of sex steroids on peripheral and pituitary endorphins. In Pancheri P, Zichella L, Falaschi P, eds. Endorphins, Neuroregulators and Behaviour in Human Reproduction. Excerpta Medica 1984:146-52
32. Genazzani AR, Trentini GP, Petraglia F, et al. Estrogens modulate the circadian rhythm of hypothalamic β-endorphin contents in female rats. Neuroendocrinology 1990;52:221-4
33. Genazzani AR, Petraglia F, Bergamaschi M, et al. Progesterone and progestins modulate β-endorphin concentrations in the hypothalamus and in pituitary of castrated female rats. Gynecol Endocrinol 1987;1:61-9
34. Genazzani AR, Petraglia F, Bergamaschi M, et al. Progesterone and progestins modulate hypothalamic and pituitary β-endorphin. In Runnebaum B, Rabe T, Kiesel L, eds. Female Contraception. Berlin, Heidelberg: Springer-Verlag, 1988:167-72
35. Genazzani AR, Petraglia F, Facchinetti F, et al. Effects of Org OD 14 on pituitary and peripheral β-endorphin in castrated rats and postmenopausal women. Maturitas 1987;1(Suppl):35-48
36. Jones CD, Jevnikar MG, Pick AJ, et al. Anti-estrogens. Structure-activity studies in a series of 3-aroyl-2-arylbenzolbthiophene derivatives leading to LY 156758, a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicity. J Med Chem 1984;27:1057-66